Jennifer A. Troia
Responsable des Ressources Humaines chez ASSEMBLY BIOSCIENCES, INC.
Profil
Jennifer A.
Troia is currently a Member at the Society for Human Resource Management and a Member at the Northern California Human Resources Association.
She is also the Chief Human Resources Officer at Assembly Biosciences, Inc. Ms. Troia previously worked as the Director at the Bay Area Human Resource Executives Council from 2003 to 2015.
She was also a Principal at COR Therapeutics, Inc. from 1996 to 2001 and at Gilead Sciences, Inc. from 1990 to 1992.
Additionally, she served as a Principal at Sunesis Pharmaceuticals, Inc. from 2013 to 2017 and as the VP-Human Resources & Corporate Operations at Sunesis Pharmaceuticals, Inc. from 2001 to 2008.
Ms. Troia was the Vice President-Human Resources & Operations at CoMentis, Inc. from 2008 to 2009.
She holds a graduate degree from the University of San Francisco.
Postes actifs de Jennifer A. Troia
| Sociétés | Poste | Début |
|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Responsable des Ressources Humaines | 01/05/2017 |
Society for Human Resource Management
 Society for Human Resource Management Miscellaneous Commercial ServicesCommercial Services The Society for Human Resource Management (SHRM) is the world's largest HR association with almost 325,000 members. The non-profit company is based in Alexandria, VA and has subsidiaries in India and the United States. The company aims to create better workplaces and address critical issues affecting society that impact work. Johnny C. Taylor has been the CEO of the company since 2017. | Corporate Officer/Principal | - |
Northern California Human Resources Association
 Northern California Human Resources Association Miscellaneous Commercial ServicesCommercial Services The Northern California Human Resources Association operates an association that connects human resources professionals with practice resources and service providers. The non-profit company is based in San Francisco, CA. | Corporate Officer/Principal | - |
Anciens postes connus de Jennifer A. Troia
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2017 |
| Bay Area Human Resource Executives Council | Directeur/Membre du Conseil | 01/12/2015 |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Directeur des opérations | 01/09/2009 |
| VIRACTA THERAPEUTICS, INC. | Responsable des Ressources Humaines | 01/08/2008 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | 01/01/2001 |
Formation de Jennifer A. Troia
| University of San Francisco | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
| Bay Area Human Resource Executives Council | |
Society for Human Resource Management
Society for Human Resource Management Miscellaneous Commercial ServicesCommercial Services The Society for Human Resource Management (SHRM) is the world's largest HR association with almost 325,000 members. The non-profit company is based in Alexandria, VA and has subsidiaries in India and the United States. The company aims to create better workplaces and address critical issues affecting society that impact work. Johnny C. Taylor has been the CEO of the company since 2017. | Commercial Services |
Northern California Human Resources Association
Northern California Human Resources Association Miscellaneous Commercial ServicesCommercial Services The Northern California Human Resources Association operates an association that connects human resources professionals with practice resources and service providers. The non-profit company is based in San Francisco, CA. | Commercial Services |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
